PATENT CLAIM ANALYSIS

Application Number: 16331579
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "260100"]

Abstract:
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Claim (Index 18):
The method according to  claim 16  wherein the cancer is selected from acute leukemias, chronic leukemias, myeloid leukemias, myelogeneous leukemias, lymphoblastic leukemias, lymphocytic leukemias, Acute myelogeneous leukemias (AML), Chronic myelogenous leukemias (CML), Acute lymphoblastic leukemias (ALL), Chronic lymphocytic leukemias (CLL), T cell prolymphocytic leukemias (T-PLL), Large granular lymphocytic leukemia, Hairy cell leukemia (HCL), MLL-rearranged leukemias, MLL-PTD leukemias, MLL amplified leukemias, MLL-positive leukemias, and leukemias exhibiting HOX/MEIS1 gene expression signatures.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 99.0
- Lexical Diversity: 1.34146
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15766887', '15537619', '15976037', '15537551', '15976223']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7650981465173103
- 35 USC 102 Novelty (BERT): 0.5306611869365321
- Combined Prediction Score: 0.7416544505592325
- Mean Citation Score: 294.28313799999995
- Max Citation Score: 308.84235
- Similarity Product: 189.1539591631829

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test